Novavax, Inc (NVAX) concluded trading on Thursday at a closing price of $7.0, with 4.76 million shares of worth about $33.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -17.70% during that period and on July 17, 2025 the price saw a gain of about 0.57%. Currently the company’s common shares owned by public are about 161.96M shares, out of which, 147.56M shares are available for trading.
Stock saw a price change of -1.41% in past 5 days and over the past one month there was a price change of -0.43%. Year-to-date (YTD), NVAX shares are showing a performance of -53.70% which decreased to -12.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.01 but also hit the highest price of $17.81 during that period. The average intraday trading volume for Novavax, Inc shares is 8.37 million. The stock is currently trading 4.66% above its 20-day simple moving average (SMA20), while that difference is up 2.62% for SMA50 and it goes to -14.21% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 161.96M outstanding shares and institutions hold larger chunk of about 56.83% of that.
The stock has a current market capitalization of $1.13B and its 3Y-monthly beta is at 2.50. PE ratio of stock for trailing 12 months is 2.64, while it has posted earnings per share of $2.65 in the same period. Its PEG reads 0.06 and has Quick Ratio of 2.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 3.69% while standing at 4.44% over the month.
Stock’s fiscal year EPS is expected to rise by 298.25% while it is estimated to decrease by -90.69% in next year. EPS is likely to grow at an annualized rate of 44.15% for next 5-years, compared to annual growth of 25.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on June 17, 2025 offering a Sell rating for the stock and assigned a target price of $6 to it. Coverage by BTIG Research stated Novavax, Inc (NVAX) stock as a Buy in their note to investors on February 28, 2025, suggesting a price target of $19 for the stock. Stock get a Neutral rating from BofA Securities on May 10, 2024.
